[The interruption of a study following an "ad interim" analysis. The example of the NSABP-P1 study].
Savarese
Antonella
A
Istituto Regina Elena, Roma.
D000328:Adult; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000453:epidemiology / Q000517:prevention & control*; D002278:Carcinoma in Situ / Q000188:drug therapy; D018275:Carcinoma, Lobular / Q000188:drug therapy; D018450:Disease Progression; D004311:Double-Blind Method; D016889:Endometrial Neoplasms / Q000139:chemically induced; D020847:Estrogen Receptor Modulators / Q000009:adverse effects / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D050723:Fractures, Bone / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D008875:Middle Aged; D009203:Myocardial Infarction / Q000517:prevention & control; D015663:Osteoporosis, Postmenopausal / Q000150:complications / Q000188:drug therapy / Q000517:prevention & control; D012306:Risk; D013629:Tamoxifen / Q000009:adverse effects / Q000627:therapeutic use*; D013923:Thromboembolism / Q000139:chemically induced; D016896:Treatment Outcome
D018931:Antineoplastic Agents, Hormonal; D020847:Estrogen Receptor Modulators; D013629:Tamoxifen